Business
A.I. Coming to Certara’s D360 Scientific Informatics Software
New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.
About this update from Certara, Inc.
[{"type":"text","content":"New deep learning capabilities will provide data and insight to inform property prioritization, novel structure design and literature-based analyses.\nPRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics software platform. The addition of novel A.I. will enable discovery scientists to integrate multiple structured and unstructured data sources and substantially enhance predictions and analysis of content related to small molecules and biologic drugs for accelerated, high confidence decisions. The upcoming rollout of D360 with advanced deep learning analytics include: Automated Property Prediction – Predictive deep learning models trained on public and proprietary chemical structure and biological data will provide quantitative or categorical predictions that improve substance prioritization.Novel Structure Generation – Deep learning models within D360 will create and optimize chemical structure ideas for assessment by discovery scientists. When combined with predictive models, users can assess newly generated chemicals alongside existing product compounds to extend the range of chemotypes relevant to project goals.Access to Unstructured Data – Traditionally, D360 has delivered insights from structured sources such as databases and web services. With the addition of large language models, users will be able to search and extract data from literature-based content to expand access to insights to inform research decisions. The new D360 A.I. capabilities are based on the advanced data fabric and deep learning platform that Certara acquired from Vyasa. Vyasa Layar and associated applications are a proven deep learning platform providing analytics capabilities within a data fabric context. “It is a pleasure to deliver deep learning-backed analytics within D360 shortly after becoming part of Certara,” said Dr. Christopher Bouton, Head of A.I. at Certara and former CEO of Vyasa, “The capabilities being added to D360 are offering biopharmaceutical companies a seamless way to accelerate innovation and decision making in drug discovery.” “Our customers turn to D360 to provide them with the insights they need to make data-backed decisions across the early drug discovery pipeline. By applying these mod...